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Most cancers emerge in the elderly, including lung cancer and mesothelioma, yet
the elderly remain an underrepresented population in pre-clinical cancer studies and
clinical trials. The immune system plays a critical role in the effectiveness of many anti-
cancer therapies in young hosts via tumor-specific T cells. However, immunosuppressive
macrophages can constitute up to 50% of the tumor burden and impair anti-tumor
T cell activity. Altered macrophage phenotype and function during aging may further
impact anti-tumor T cell responses. Yet, the impact of macrophages on anti-tumor T
cell responses and immunotherapy in the elderly is unknown. Therefore, we examined
macrophages and their interaction with T cells in young (3 months) and elderly (20–
24 months) AE17 mesothelioma-bearing female C57BL/6J mice during tumor growth.
Mesothelioma tumors grew faster in elderly compared with young mice, and this
corresponded with an increase in tumor-associated macrophages. During healthy
aging, macrophages increase in bone marrow and spleens suggesting that these sites
have an increased potential to supply cancer-promoting macrophages. Interestingly, in
tumor-bearing mice, bone marrow macrophages increased proliferation whilst splenic
macrophages had reduced proliferation in elderly compared with young mice, and
macrophage depletion using the F4/80 antibody slowed tumor growth in young and
elderly mice. We also examined responses to treatment with intra-tumoral IL-2/anti-
CD40 antibody immunotherapy and found it was less effective in elderly (38% tumor
regression) compared to young mice (90% regression). Tumor-bearing elderly mice
decreased in vivo anti-tumor cytotoxic T cell activity in tumor draining lymph nodes and
spleens. Depletion of macrophages using F4/80 antibody in elderly, but not young mice,
improved IL-2/anti-CD40 immunotherapy up to 78% tumor regression. Macrophage
depletion also increased in vivo anti-tumor T cell activity in elderly, but not young
mice. All the tumor-bearing elderly (but not young) mice had decreased body weight
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(i.e., exhibited cachexia), which was greatly exacerbated by immunotherapy; whereas
macrophage depletion prevented this immunotherapy-induced cachexia. These studies
strongly indicate that age-related changes in macrophages play a key role in driving
cancer cachexia in the elderly, particularly during immunotherapy, and sabotage elderly
anti-tumor immune responses.
Keywords: macrophage, aging, cancer, immunotherapy, T cells, cachexia
INTRODUCTION
Life expectancy of the human global population is increasing.
However, health deterioration with aging is associated with an
increased incidence of cancers, including mesothelioma, in the
elderly. The immune system plays a crucial role in eliminating
cancerous cells, however, immune function can decline with age,
termed “immunosenescence” (Pawelec and Solana, 1997). One
thought is that immunosenescence occurs as a consequence of
life-long exposure to antigenic stress and inflammation (Pawelec,
2012). Chronic, low grade inflammation is also reported with
aging, referred to as “inflammaging” (Franceschi et al., 2007).
This is characterized by increased circulating levels of pro-
inflammatory cytokines, such as tumor necrosis factor (TNF)-α
and interleukin (IL)-6 (Franceschi et al., 2000, 2007; Castelo-
Branco and Soveral, 2014). Concurrently, elevated levels of anti-
inflammatory cytokines, such as transforming growth factor
(TGF)-β and IL-10, have been reported (Carrieri et al., 2004;
Lio et al., 2004; Franceschi et al., 2007; Castelo-Branco and
Soveral, 2014), which may regulate the inflammatory aging
microenvironment. Disturbance of the balance between pro-
and anti-inflammatory factors may impact on physiological
function of the host and account for the increasing cancer rates
in the elderly population. Furthermore, age-related changes in
thymic function and T cells have also been proposed as a major
contributor to the increased cancer incidence in older humans
(Palmer et al., 2018).
The immune system plays a crucial role in host defense
against cancer through recognition and elimination of cancerous
cells primarily by tumor-specific cytotoxic T lymphocytes (CTLs;
Chen and Mellman, 2013). Anti-tumor CTLs are generated
by interaction with antigen presenting cells (APCs), including
dendritic cells and macrophages (Chen and Mellman, 2013).
Tumor antigen presentation by APCs and subsequent activation
of T cells generally occurs in draining lymph nodes (DLNs)
and effective tumor cell killing requires activated CTLs to traffic
to the tumor site (Gardner and Ruffell, 2016). However, this
complex process can fail due to the tumor employing escape
mechanisms (Speiser et al., 2016), leading to disease progression.
As a result, immunotherapies have been designed that aim to
induce or enhance specific anti-tumor immunity mediated by
CTLs (Rosenberg, 2014). Yet, T cell function is also compromised
during aging (Koch et al., 2008; Fulop et al., 2010) and therefore
some T cell-based immunotherapies in the elderly may be less
effective.
Anti-tumor T cells must overcome an immunosuppressive
tumor microenvironment in order to eliminate tumor cells
(Speiser et al., 2016). Key mediators of immunosuppression in
the tumor are tumor-associated macrophages (TAMs), which can
make up to 50% tumor burden and are often correlated to poor
prognosis (Luo et al., 2006; Zhang et al., 2012, 2016; Fritz et al.,
2014). It has been proposed that tumor evolution starts with
chronic inflammation wherein pro-inflammatory macrophages
secreting cytokines such as IL-6 and TNF-α promote neoplastic
transformation (Sica et al., 2008; Biswas and Mantovani, 2010).
Tumor-derived factors such as C-C ligand 2 (CCL2) and colony
stimulating factor-1 (CSF-1) can also recruit further macrophages
to the tumor from the bone marrow (BM) and spleen (Cortez-
Retamozo et al., 2012). Once established, tumor-derived factors
drive macrophages toward an immunosuppressive phenotype
which impairs anti-tumor T cell activity, primarily through the
secretion of anti-inflammatory cytokines/chemokines such as
TGF-β, IL-10, CCL17, and CCL22 (Biswas and Mantovani, 2010;
Jackaman et al., 2017).
Several lines of evidence indicate dysregulated macrophage
function with aging (Oishi and Manabe, 2016). For example,
in vitro splenic macrophages from elderly female Balb/c mice
(aged 18–20 months) were hyposensitive to pro-inflammatory
lipopolysaccharide (LPS) stimuli, with reduced production of
TNF-α and IL-1β compared to young mice (Mahbub et al.,
2012). However, in separate studies BM-derived macrophages
from elderly female C57BL/6J mice (aged 16–22 months)
exhibited increased TNF-α and IL-6 production in response
to LPS (Bouchlaka et al., 2013; Thevaranjan et al., 2017).
Similarly, elderly derived female Balb/c (aged 17–18 months)
and C57BL/6J peritoneal macrophages (aged 24–28 months)
displayed hypersensitivity to anti-inflammatory IL-4 stimuli with
increased production of anti-inflammatory IL-10 and TGF-β
(Jackaman et al., 2013, 2014). In vivo murine studies have also
described macrophages from the eye, muscles, lymph nodes,
spleen and bone marrow expressing increased IL-10 during
aging (Wang et al., 1995, 2015; Kelly et al., 2007; Jackaman
et al., 2013). However, liver and adipose tissue macrophages
from elderly male and female C57BL/6J mice (18–22 months)
express increased pro-inflammatory IL-6 and TNF-α (Lumeng
et al., 2011; Fontana et al., 2013). It is likely that each tissue
microenvironment will exert distinct influences on macrophage
phenotype during aging which may account for the discrepancies
between these studies. However, the impact of the tumor
microenvironment on macrophages during aging remains largely
unknown.
We have previously shown that local intra-tumoral
administration of IL-2/anti-CD40 immunotherapy induces
mesothelioma tumor regression in young (aged 2–3 months)
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female C57BL/6J mice (Jackaman et al., 2008, 2016; Jackaman
and Nelson, 2012); mediated primarily by neutrophils, CTLs
and macrophages. This response included the generation of
anti-tumor CTLs and polarization of macrophages into a pro-
inflammatory phenotype within DLNs in young mice in vivo
(Jackaman et al., 2016). Similarly, we have shown that IL-2/anti-
CD40-activated macrophages can rescue age- and tumor-induced
T cell function in vitro (Jackaman et al., 2013, 2014). However, it
is likely that the inflammaging microenvironment plays a pivotal
role in age-related macrophage dysfunction (Oishi and Manabe,
2016) and further in vivo studies are required.
Aging is a risk-factor for cancer-associated cachexia (Ali and
Garcia, 2014; Wallengren et al., 2015), which is characterized by
loss of body weight or skeletal muscle atrophy (Fearon et al.,
2011). The diagnosis of cachexia often marks a decline in survival
with poor responses to anti-cancer therapy and the severity
is not necessarily associated to tumor size (Ross et al., 2004;
Fearon, 2008, Fearon et al., 2012). Cancer cachexia is possibly
due to metabolic dysfunction and is associated with the same
inflammatory cytokines that are elevated with inflammaging
(e.g., IL-6 and TNF-α; (Franceschi et al., 2000, 2007; Castelo-
Branco and Soveral, 2014). Moreover, tumor- and host-derived
cytokines, potentially released by TAMs, may contribute to
cachexia (Billingsley et al., 1996; Fearon et al., 2012). However,
few pre-clinical models have examined the contribution of
macrophages to cancer cachexia in elderly mice.
Therefore, to address this issue we examined the role of
macrophages in young (3 months) vs. elderly (20–24 months)
mesothelioma-bearing female C57BL/6J mice during tumor
growth and following treatment with intra-tumoral IL-2/anti-
CD40 immunotherapy. We used flow cytometry to assess the
percentage of macrophages in spleen, bone marrow (BM),
and tumors, as well as macrophage proliferation via Ki67.
Macrophages were depleted in vivo using F4/80 antibody and
mice monitored for response to IL-2/anti-CD40 immunotherapy,
as well as weight loss (i.e., cachexia). In order to assess the
impact of macrophage depletion on T cell function, in vivo
anti-tumor CTL analyses was performed in IL-2/anti-CD40
treated mice ± macrophage depletion. Taken together, our
findings suggest that macrophages in the elderly facilitate faster
mesothelioma tumor growth, leading to impairment of anti-
tumor immune responses and cancer cachexia.
MATERIALS AND METHODS
Mice
Female C57BL/6J mice aged 3 months (young, equivalent to
18-year-old humans) and 20–24 months (elderly, equivalent to
60–70-year-old humans), as defined by the Jackson Laboratory
(Yuan et al., 2009), were obtained from the Animal Resources
Center (ARC, Murdoch, WA, Australia). In this study we
analyzed 20–24 months as the lifespan of C57BL/6J mice
significantly declines after 24 months due to the development of
comorbidities and age-related pathologies (less than 50% survival
post 24 months, Yuan et al., 2009). All mice were maintained
in specific pathogen free conditions with 3–5 mice/cage on corn
cob bedding at Curtin University animal facilities. Prior to tumor
inoculation, mice were excluded from the study if they had a
palpable mass, enlarged organs (such as liver, lymph nodes, and
spleen) or exhibited excessive body weight loss (>15% from age
12 months). Animals were housed in a standard light/dark cycle
and sample collection performed in the morning. Experiments
were performed as per the Curtin University Animal Ethics
Committee (AEC) in accordance to the Australian Code of
Practice for the use and care of animals for scientific purposes
(AEC approval numbers: AEC_2012_21 and AEC_2016_05).
AE17 and AE17-sOVA Murine
Mesothelioma Cell Lines
AE17 is a murine malignant mesothelioma cell line generated by
inoculation of asbestos fibers and was derived from orthotopic
tumor deposits that emerged in elderly C57BL/6J mice.
When inoculated subcutaneously (s.c.) AE17 is histologically
representative of human mesothelioma (Jackaman et al., 2003).
AE17 has been transfected with ovalbumin (AE17-sOVA) as
a surrogate tumor marker (Jackaman et al., 2003). AE17-
sOVA tumor growth and response to immunotherapy is
similar to AE17. Cells were maintained in complete medium,
containing RPMI 1640 (Invitrogen) supplemented with 10%
fetal calf serum (FCS; ThermoScientific), 2 mM L-glutamax
(Life Technologies, Victoria, VIC, Australia), 100 units/ml of
penicillin, 100 µg/ml streptomycin (Life Technologies) and
0.05 mM 2-mercaptoethanol (Sigma-Aldrich) at 37◦C with 5%
CO2. For AE17sOVA this also included G418 Geneticin as a
selection antibiotic (Life Technologies). Cells were collected for
tumor inoculation when ≥80% confluent. Mice were inoculated
s.c. with 5 × 105 AE17 or AE17-sOVA cells in 100 µl PBS
and body weight, body condition score and tumors monitored
daily. All tumor size measurements were performed on animals
using calipers and each mouse was individually tracked for tumor
growth. Tumor size was determined by daily measurement of
tumor width (mm) and tumor length (mm), and size calculated
as width × length as mm2. Mice were monitored until their
individual maximum tumor size reached 140 mm2 or weight loss
exceeded >20% as per AEC conditions. For tumor-bearing mice,
percentage change in body weight was calculated from the start
of treatment (PBS or IL-2/anti-CD40±macrophage depletion).
Macrophage Depletion and
IL-2/anti-CD40 Antibody Treatment
F4/80hi macrophages were depleted using anti-F4/80 antibody
(similar to Tidball and Wehling-Henricks, 2007; Bedoret et al.,
2009) early during tumor growth 1–9 mm2. Mice were treated
daily, alternating between intra-peritoneal (i.p.) and intra-
tumoral (i.t.) injections with 100 µg of the antibody or phosphate
buffered saline (PBS; diluent control) for up to 10 days.
Endotoxin levels of these antibodies are less than 0.1 EU/ml
(Absolutions, Perth, WA, Australia). Proleukin IL-2 (20 µg/dose;
Cetus Corporation) and anti-CD40 antibodies (40 µg/dose;
FGK45, Absolutions) were used as combination immunotherapy
as previously described (Jackaman et al., 2008; Jackaman and
Nelson, 2012). Mice were treated intra-tumorally every 2–3 days
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for a total of five treatments. Mice were considered to have
survived if they had complete tumor regression at 50 days
following the start of treatment. We have previously confirmed
that the antibody isotype does not influence tumor growth as a
further control for depletion and anti-CD40 antibody (Jackaman
et al., 2016).
To assess whether depletion efficiency was similar between
young and elderly mice, in a separate experiment mice were
sacrificed mid-way through treatment ± depletion (at day 15)
when tumor size was similar between groups. Tumor samples
were disaggregated into a single cell suspension by gentle
dispersion between two frosted slides, followed by blocking
with anti-mouse CD16/32 antibodies (Biolegend) for 15 min
on ice and then staining with anti-F4/80-Alexafluor R© 647 for
30 min (Biolegend). Samples were then washed twice in PBS
containing 2% FCS followed by acquisition on LSRFortessaTM
using FACSDiva (BD Bioscience). Data were analyzed using
FlowJo version 10.2 (Tree Star, Inc., Ashland, OR, United States).
Macrophage depletion was effective at reducing F4/80hi cells and
led to a 43.9% reduction in young mice tumor samples with a
40.7% reduction in elderly mice tumor samples(Supplementary
Figure S1). As a further control, to confirm that the F4/80
antibody used in flow cytometry bound a different epitope to
the depleting F4/80 antibody, BM-derived macrophages were
pre-incubated with depleting F4/80 antibody followed by flow
cytometry staining with anti-F4/80-Alexafluor R© 647 antibody
as described above. Pre-incubation with depleting anti-F4/80
antibody did not prevent flow cytometry staining, confirming
these two antibodies bound different epitopes.
Flow Cytometry
BM, spleen, lymph nodes, and tumors were collected into
staining/collection buffer: ice-cold PBS containing 2% FCS
and 2 mM EDTA (Sigma-Aldrich). Tibia and femur were
flushed using a 29 g needle to isolate BM cells. Tissue
samples were disaggregated into single cell suspensions with
gentle dispersion between two frosted slides in staining buffer.
Cells were blocked with anti-mouse CD16/32 antibodies (clone
93, Biolegend) for 15 min on ice and all subsequent steps
were performed on ice in the dark. A combination of the
following anti-mouse antibodies were incubated for 30 min: anti-
F4/80-Alexafluor R© 647 (clone BM8, Biolegend), anti-CD11b-
Alexafluor R© 488 (clone M1/70, Biolegend), anti-Ly6C-Brilliant
Violet 510TM (clone HK1.4, Biolegend), anti-Ly6G-Brilliant
Violet 785TM (clone 1A8, Biolegend), anti-CX3CR1-Brilliant
Violet 650TM (clone SA011F11, Biolegend), and anti-CD170
(Siglec-F)-PerCP-eFluor R© 710 (clone 1RNM44N, eBioscience).
Samples were washed in staining buffer (PBS/2%FCS/2mM
EDTA), followed by PBS and incubated for 15 min with
Zombie-NIRTM (Biolegend). Samples were then washed twice
with PBS, followed by fixation and permeabilization with True-
Nuclear Transcription Factor Buffer Set as per manufacturer’s
instructions (Biolegend) for intracellular staining. Samples were
incubated with anti-Ki67-PE (clone 16A8, Biolegend; diluted
in True-Nuclear Transcription Factor permeabilization buffer,
Biolegend), then washed twice and resuspended in staining
buffer for acquisition on LSRFortessaTM using FACSDiva (BD
Bioscience). Data were analyzed using FlowJo version 10.2 (Tree
Star, Inc). Unstained and relevant isotype controls were included
as negative controls and fluorescence minus one controls were
used as gating controls.
In vivo Cytotoxic T Lymphocyte (CTL)
Assay
Spleen and lymph nodes from naïve C57BL/6J mice were
disaggregated into a single cell suspension using two frosted
glass slides, followed by pulsing with 5 µg/ml of SIINFEKL
for 90 min at 37◦C in RPMI/10%FCS. Uncoated control cells
were also incubated for 90 min at 37◦C in RPMI/10%FCS.
Following incubation, the cells were washed in RPMI/10%FCS.
Cells were then labeled in RPMI without FCS with either a high
concentration of carboxyfluorescein succinimidyl ester (CFSE,
5 µM, SIINFEKL population) or low concentration of CFSE
(0.5 µM, control cells), incubated at room temperature in the
dark for 10 min. Following incubation, cells were washed twice in
RPMI/10%FCS with an FCS underlay followed by two washes in
PBS. For i.v. injection 1× 107 cells of each population were mixed
equally in 400 µl PBS per recipient mouse. Tumor, DLNs and
spleens were collected from recipient mice (young and elderly
AE17-sOVA mice treated with either PBS or IL-2/anti-CD40
immunotherapy + /− macrophage depletion) 16–18 h post i.v.
injection. Samples were prepared as a single cell suspension
and analyzed by flow cytometry. Further controls included
naïve healthy mice, AE17 tumor-bearing mice (with or without
immunotherapy) and untreated recipient mice. To normalize
data, percent CTL activity was expressed relative to the no
tumor naïve control mice included in every experiment. Relative
killing in experimental groups was calculated by determining the
percentage of peptide-coated target cells relative to uncoated cells,
normalized to the no tumor control mice, then multiplying by
100 to obtain a percentage value.
Statistical Analysis
GraphPad Prism version 7 (California, CA, United States) was
used for statistical analysis. Differences between two populations
were determined using the Mann-Whitney U-test. A relationship
between two variables was determined by Pearson’s correlation
coefficient test. Results expressed as mean ± SEM. P-values of
<0.05 were considered statistically significant.
RESULTS
Mesothelioma Tumors Grow Faster in
Elderly Mice
As few studies have examined the effects of aging on tumor
growth, including mesothelioma, we first aimed to investigate
AE17 mesothelioma tumor growth in young vs. elderly mice.
Tumor cells were inoculated into young and elderly C57BL/6J
mice and mice monitored for tumor growth. We observed that
from approximately day 10, mesothelioma tumors grew faster in
elderly compared with young mice (Figure 1A). Moreover, tumor
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weight at the same endpoint was significantly higher in elderly
mice (Figure 1B).
Tumor-Associated Macrophages (TAMs)
Increase as Tumors Get Larger
Tumor-associated macrophages can play a key role in tumor
growth, including mesothelioma (Jackaman et al., 2016), and
their numbers are often associated with poor prognosis (Luo
et al., 2006; Zhang et al., 2012, 2016; Fritz et al., 2014). Given
the faster tumor growth in elderly mice, we next assessed the
percentage of TAMs in tumors from young and elderly mice. Flow
cytometry analysis (gating strategy in Figure 2A) showed that
the percentage of CD11b+F4/80+Ly6G−Siglec-F− macrophages
was significantly increased in tumors of elderly compared with
young mice (Figure 2B) and was associated with increasing
tumor weight (Figure 2C), i.e., larger tumors have a greater
percentage of macrophages. Proliferation in situ may account for
TAMs expansion in elderly tumors, therefore we next analyzed
the proliferation marker Ki67 (example flow cytometry plots in
Figure 2D). In both young and elderly tumors, >50% of TAMs
were proliferating, however, there were no age-related differences
(Figure 2E). Furthermore, TAM proliferation was not associated
with tumor size (Supplementary Figure S2). Therefore, it is
possible that increased TAMs in elderly tumor-bearing mice may
be due to an increased supply from other tissue sites.
Macrophages Increase in Elderly Mice
and Have Altered Proliferative Potential
in Lymphoid Tissues in Response to
Mesothelioma
We next examined BM and spleen to assess whether the
presence of tumor influences macrophages in these tissues,
particularly as these two sites can potentially contribute
macrophages to the tumor (Cortez-Retamozo et al., 2012).
Similar to previous studies, the proportion of macrophages
(CD11b+F4/80+Ly6G−Siglec-F−) in the BM and spleen
increased during healthy aging, however, this did not further
increase during mesothelioma tumor growth (Wang et al.,
1995; Jackaman et al., 2013; (Supplementary Figure S3). This
suggests that these sites have a larger pool of macrophages
in elderly mice and there may be increased potential to
supply macrophages to the tumor in elderly mice. To further
investigate macrophages in the BM and spleen, we measured
in vivo proliferation via Ki67 during AE17 mesothelioma
tumor growth. Whilst BM macrophage proliferation did not
change in response to mesothelioma in young mice, elderly
mice significantly increased proliferation compared with
healthy controls and young tumor-bearing mice (example
Ki67 staining in Figure 3A and pooled data in Figure 3B).
In contrast, we observed decreased proliferation in splenic
macrophages in elderly hosts with tumor (example Ki67
staining in Figure 3C and pooled data in Figure 3D). This
suggests cross-talk occurs between the tumor and lymphoid
tissues in the elderly microenvironment. This may also have
the potential to further influence tumor growth in the elderly
as previous studies have shown that the spleen and BM can
supply macrophages to the tumor site (Cortez-Retamozo et al.,
2012).
Macrophage Depletion Improves
IL-2/anti-CD40 Immunotherapy and
Reduces Cachexia in Elderly Mice
We have previously shown that intra-tumoral IL-2 combined
with anti-CD40 antibody leads to AE17 mesothelioma tumor
regression in young mice; this was associated with increased
CTL activity (Jackaman et al., 2008, 2016). Furthermore, in vitro
FIGURE 1 | Mesothelioma tumors grow faster in elderly mice. Young (n = 15) and elderly (n = 13) C57BL/6J mice were inoculated s.c. with 5 × 105 AE17
mesothelioma tumor cells and tumor growth monitored. Tumor size was determined by daily measurement of tumor width (mm) and tumor length (mm) using
calipers, and size calculated as width × length as mm2 (A). Tumor weight was recorded at endpoint (day 21–23, n = 7 young mice and 8 elderly mice), based on the
maximum allowed size (140 mm2; B). Data is pooled from three experiments shown as mean ± SEM. ∗∗p < 0.01, ∗∗∗p < 0.005, #p < 0.001.
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FIGURE 2 | TAMs increase in tumors of elderly mice. AE17 mesothelioma tumors were collected from young (n = 7) and elderly C57BL/6J mice (n = 8) at day 21–23,
based on the maximum allowed size (140 mm2; tumor size calculated as width × length measured using calipers). Tumor samples were dissociated into single cell
suspension, stained for CD11b, F4/80, Ly6G, Siglec-F, viability dye and intracellular Ki67 and analyzed via flow cytometry. Macrophages were identified as
CD11b+F4/80+Ly6G-Siglec-F- (representative gating strategy shown in (A). Macrophages are shown as % total cells (B) and correlated to tumor weight (C).
Example flow cytometry plots for Ki67 staining are shown in (D), and pooled data for % proliferation (by Ki67 staining % positive) of TAMs in (E). Data is pooled from
three experiments shown as mean ± SEM; ∗p < 0.05.
studies showed that elderly derived IL-2/anti-CD40-activated
macrophages could restore age- and tumor-related T cell function
(Jackaman et al., 2013, 2014). Therefore, we next examined
whether IL-2/anti-CD40 was effective in young vs. elderly AE17
tumor-bearing mice and whether macrophages contributed to
the efficacy of IL-2/anti-CD40 immunotherapy. Firstly, depletion
of macrophages without immunotherapy treatment, resulted in
slower tumor growth for both age groups relative to non-depleted
controls (Figures 4A,B). Macrophage depletion was effective at
inhibiting growth of small tumors ≤9 mm2 in both age groups
and had no impact on tumor growth if depletion was commenced
at ≥16 mm2 (data not shown).
Immunotherapy in young mice led to full tumor regression
(Figure 4C) and 90% survival at 50 days after start of the
treatment (Figure 4E). However, macrophage inhibition during
IL-2/anti-CD40 immunotherapy in young mice led to tumor
outgrowth (Figure 4C) and only 43% survival (Figure 4E).
In contrast, immunotherapy in elderly mice was less effective
in preventing tumor outgrowth (Figure 4D) and led to only
38% survival at 50 days (Figure 4E). Inhibition of macrophages
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FIGURE 3 | Macrophages have altered proliferative potential in lymphoid
tissues in response to mesothelioma tumor. Young (n = 9) and elderly
C57BL/6J mice (n = 9) were inoculated with s.c. with 5 × 105 AE17
mesothelioma tumor cells and sacrificed at day 21–23, based on the
maximum allowed size (140 mm2; tumor size calculated as width × length
measured using calipers). Healthy control mice were also included (n = 8 for
young and n = 9 for elderly). Spleen and bone marrow samples were
dissociated into single cell suspensions, stained for CD11b, F4/80, Ly6G,
Siglec-F, viability dye and intracellular Ki67 and analyzed via flow cytometry.
Macrophages (CD11b+F4/80+Ly6G-Siglec-F-) were measured for
proliferation via Ki67 staining (shown as % positive) in the BM (example plots
shown in A, pooled data in B) and spleen (example plots shown in C, pooled
data in D) of young and elderly healthy and AE17 tumor bearing mice. Data is
pooled from three experiments shown as mean ± SEM. ∗∗p < 0.01.
in elderly mice improved the response to IL-2/anti-CD40
immunotherapy leading to a reduction in tumor growth
(Figure 4D) and improved survival (78%, Figure 4E). These data
show that macrophages are required for immunotherapy to be
effective in young mice, yet impair responses to immunotherapy
in elderly mice.
Interestingly, we also found that only elderly (and not
young) tumor-bearing mice exhibited significant body
weight loss (cachexia) which was severely exacerbated by
the immunotherapy (Figure 4F, body weights are shown
for mice examined during treatment from approximately
day 12–24). This suggests that elderly mice are more
susceptible to cancer cachexia, and that immunotherapy
accelerates the cachexia. Furthermore, in elderly, but not
young mice, macrophage inhibition prevented the IL-
2/anti-CD40 immunotherapy treatment-induced cachexia
(Figure 4F).
Macrophages Play a Role in Sabotaging
Anti-tumor CTLs in Elderly
Tumor-Bearing Mice
In order to determine whether CTL activity was altered during
aging following macrophage depletion and immunotherapy, we
next performed in vivo CTL analyses in AE17sOVA tumor-
bearing mice ± IL-2/anti-CD40 immunotherapy ± macrophage
depletion. In young mice, immunotherapy led to a trending
increase (although non-significant) in CTL activity in the DLN,
spleen and tumor (Figure 5A shows example flow cytometry
plots and pooled data in Figures 5B–D). However, macrophage
depletion combined with immunotherapy decreased CTL activity
in the DLN and spleen of young mice. During aging, without
immunotherapy, CTL activity was impaired in elderly PBS
controls compared with young PBS control mice in DLN,
spleen and tumor (Figure 5A example plots and pooled data
in Figures 5B–D). IL-2/anti-CD40 immunotherapy alone did
not significantly improve CTL activity in DLN, spleen or
tumor of elderly mice. Interestingly, combining macrophage
depletion with immunotherapy increased CTL activity in elderly
DLN, spleen and tumor (Figures 5B–D). Overall, these data
highlight that macrophages are required for CTL activity during
immunotherapy in young mice, yet play a role in impairing CTL
activity in elderly mice during immunotherapy.
DISCUSSION
Studies have shown that macrophages play a role in tumor
progression (Luo et al., 2006; Zhang et al., 2012; Fritz et al.,
2014; Jackaman et al., 2017) and several lines of evidence
indicate these cells are dysregulated with aging (Mahbub et al.,
2012; Bouchlaka et al., 2013; Jackaman et al., 2013; Oishi
and Manabe, 2016; Thevaranjan et al., 2017). However, few
studies have examined the role of macrophages in cancer during
aging. Therefore, we aimed to examine whether macrophage
dysregulation in the elderly impacted tumor progression
and responses to immunotherapy. Our data showed marked
differences in the growth of mesothelioma tumors and that
cachexia is greatly increased by immunotherapy in elderly mice;
confirming a central role for macrophages in these age-related
responses. Interestingly, macrophages also played a key role in
suppressing anti-tumor T cell activity during immunotherapy.
These observations in mice are discussed in detail below in
the context of potential implications for elderly cancer patients,
efficacy of cancer immunotherapies and severity of cachexia.
Our data showed that mesothelioma tumors grew faster
in elderly mice which coincided with increased TAMs.
The percentage of TAMs in tumors positively correlated
with tumor size rather than in situ TAM proliferation.
Macrophages increased in the aging spleen whilst elderly
BM macrophages demonstrated enhanced proliferation in
response to mesothelioma. This suggests that augmented
supply of BM macrophages in elderly mice may account for
increased TAMs and faster tumor growth. Other studies have
also shown an age-associated increase of macrophages in the
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FIGURE 4 | IL-2/anti-CD40 immunotherapy is less effective in elderly mice and accelerates cachexia. Young (n = 9/group) and elderly (n = 10/group) C57BL/6J mice
were inoculated s.c. with 5 × 105 AE17 mesothelioma tumor cells and macrophage-depleted using anti-F4/80 antibody when tumors were palpable (1–9 mm2;
tumor size calculated as width × length measured using calipers). Mice were injected daily for 10 days, alternating between i.p. and i.t. administration (100 µg/dose
in 100 µl PBS). PBS diluent or antibody isotype control was used for control mice. Pooled data from three experiments is shown for macrophage depletion, without
immunotherapy, for young mice (A) and elderly mice (B) as mean ± SEM. In separate experiments, young (n = 10–14/group) and elderly (n = 9–11/group) C57BL/6J
mice were inoculated s.c. with 5 × 105 AE17 mesothelioma tumor cells. Macrophages were depleted using anti-F4/80 antibody 2 days prior to the start of
IL-2/anti-CD40 immunotherapy. Anti-F4/80 antibody was injected daily for 10 days, alternating between i.p. and i.t. (100 µg/dose in 100 µl PBS). When tumors
reached 15–21 mm2 (tumor size calculated as width × length measured using calipers) i.t. IL-2/anti-CD40 immunotherapy (20 µg IL-2 and 40 µg anti-CD40 Ab,
100 µl/dose in PBS) was administered every 2–3 days for five treatments. Pooled data from three experiments is shown for macrophage
depletion + immunotherapy for young mice tumor growth (C), elderly mice tumor growth (D) and survival for both (E) as mean ± SEM. The percentage change in
body weight was calculated from the start of treatment (PBS or IL-2/anti-CD40 ± macrophage depletion) and compared to age-matched healthy controls (F). Data
shown as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, #p < 0.001.
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FIGURE 5 | Macrophages sabotage anti-tumor CTL activity during immunotherapy in elderly mice. Young (n = 6–9/group) and elderly (n = 7–9/group) C57BL/6J
mice were inoculated s.c. with 5 × 105 AE17-sOVA mesothelioma tumor cells. Macrophages were depleted using anti-F4/80 antibody 2 days prior to the start of
IL-2/anti-CD40 immunotherapy. Anti-F4/80 antibody was injected daily, alternating between i.p. and i.t. (100 µg/dose in 100 µl PBS). When tumors reached
15–21 mm2 (tumor size calculated as width × length measured using calipers) i.t. IL-2/anti-CD40 immunotherapy (20 µg IL-2 and 40 µg anti-CD40 Ab, 100 µl/dose
in PBS) was administered every 2–3 days. In vivo CTL activity was assessed following two doses of i.t. IL-2/anti-CD40 immunotherapy when tumor size was similar
between groups. Target cells pooled from LNs and spleen cells of naïve C57BL/6J mice were pulsed with SIINFEKL (SIIN) and labeled with a high concentration of
CFSE. No peptide control cells (CTRL) were labeled with a low concentration of CFSE. These populations were pooled equally and injected i.v. into mice for flow
cytometry analysis 16–18 h later (example DLN plots in A). CTL activity was calculated as a percentage, based on reduction of the SIINFEKL population relative to
the no peptide control population in DLN (B), spleen (C) and tumor (D). Data is pooled from three experiments shown as mean ± SEM, with the average value
above each bar graph. ∗p < 0.05, ∗∗p < 0.01, #p < 0.001.
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spleen (Loukov et al., 2016), blood (Stranks et al., 2015), and
BM (Wang et al., 1995). Furthermore, expansion of myeloid
precursors is reported with aging (Dykstra et al., 2011; Pang
et al., 2011; Loukov et al., 2016; Ho et al., 2017), allowing
rapid production of monocyte/macrophages in response to
immunological challenge (Kovtonyuk et al., 2016). This process
may be linked to inflammaging, as increased circulating levels of
pro-inflammatory cytokines, such as TNF-α and IL-6, can drive
hematopoietic stem cells toward the myeloid lineage (Loukov
et al., 2016). The increased pool of macrophage progenitors with
aging may have consequences for CSF-1 producing cancers,
including AE17 murine mesothelioma (Demetri et al., 1989;
Fox et al., 2012). CSF-1 is a growth factor required for the
proliferation, differentiation, and survival of macrophages
(Pixley and Stanley, 2004). Furthermore, CSF-1 can also act
as a chemoattractant for monocyte/macrophages (Shaposhnik
et al., 2010). This may be important in the context of the aging
microenvironment, as tumor-derived CSF-1 could circulate to
stimulate macrophage population expansion in various tissues
and also help to chemoattract such macrophages to the tumor,
further driving macrophage-mediated tumor growth in the
elderly.
Recent studies by Netea et al. (2016) in young
mice and humans have described a paradigm shift in
monocyte/macrophage biology in that these cells can develop
a form of non-specific immunological memory or “training”
(Quintin et al., 2012; Cheng et al., 2014; Saeed et al., 2014). This
training results in a heightened pro-inflammatory phenotype or
immune tolerance, characterized by altered cytokine production,
following exposure to the same or another agent (Netea et al.,
2016). Further, recent studies have described that trained
immunity can occur at the level of macrophage precursors
in the BM and is associated with a shift toward the myeloid
lineage in the BM (Mitroulis et al., 2018), similar to the shift
that occurs during aging described above (Dykstra et al., 2011;
Pang et al., 2011; Loukov et al., 2016). Correspondingly, the
cytokines associated with inflammaging (e.g., TNF-α, IL-6, IL-1β,
MCP-1, and IL-10 (Franceschi et al., 2007) are also similar to
those associated with a training phenotype. It is possible that the
aging environment leads to macrophage training as suggested
by others (Fulop et al., 2016; Franceschi et al., 2017) which is
further enhanced by the tumor microenvironment. A similar
study which also supports this hypothesis administered IL-
2/anti-CD40 systemically to elderly female C57BL/6J mice (aged
16–22 months) leading to acute inflammatory-induced pathology
due to macrophage-derived TNF-α production (Bouchlaka et al.,
2013). Whether training is a mechanism behind macrophage
dysfunction during aging remains to be determined and warrants
further investigation.
Interestingly, our study showed that macrophages from
the BM and spleen showed opposing proliferative capacity in
response to aging and mesothelioma; with BM macrophages
showing increasing proliferation and splenic macrophages
decreasing proliferation. It is possible that longer period
of exposure to the aging environment may account for
decreased proliferative potential in terminally differentiated
splenic macrophages (Stout and Suttles, 2005; Wang et al.,
2013). This may be further exacerbated with cancer leading to
replicative senescence in macrophages; as previously described
in T cells where cancer leads to a burst of proliferation
followed by senescence (Chou and Effros, 2013). Further, recent
studies have suggested that macrophage origin may influence
their response. BM-derived macrophages minimally contribute
to tissue-resident populations during homeostasis (Ginhoux
et al., 2010), instead they are recruited during inflammation or
cancer development. During states of inflammation, the BM can
also outsource the production of monocytes to extramedullary
sites such as the spleen, leading to storage, amplification
and deployment of monocytes in response to inflammatory
signals or cancer (Cortez-Retamozo et al., 2012; Shand et al.,
2014). Therefore, it is possible that macrophages from the
spleen have been exposed for longer to the inflammatory aging
microenvironment, relative to the BM, leading to a senescent
phenotype; hence, reduced proliferation in aging which is further
exacerbated with cancer.
We have previously shown that local IL-2/anti-CD40
immunotherapy can enhance anti-tumor T cell activity
and intra-tumoral inflammation leading to resolution of
mesothelioma tumors in young (aged 2–3 months) female
C57BL/6J mice (Jackaman et al., 2008, 2016; Jackaman and
Nelson, 2012). However, in elderly mice this was less effective
and associated with a decline in T cell activity, similar to
previous studies (Provinciali et al., 2000; Gravekamp et al.,
2008; Castro et al., 2009). Interestingly, our data suggest that
macrophages impair anti-tumor T cell responses in elderly mice
during immunotherapy as macrophage depletion improved
outcomes in elderly but not young mice. In contrast, macrophage
depletion in young mice impaired immunotherapy and anti-
tumor CTL activity. This could be via direct T cell interaction
or indirectly through cytokine production and activation of
dendritic cell (DC) function (Sharma et al., 2006; Gardner and
Ruffell, 2016). We have previously shown that elderly derived
macrophages display a heightened response to tumor-derived
factors, leading to increased production of TGF-β and IL-10
(Jackaman et al., 2013). This would likely drive DCs to induce T
cell tolerance in the aged tumor microenvironment (Esebanmen
and Langridge, 2017). Consistent with this, our corresponding
DC studies (Gardner et al., under review) show that DCs
upregulate numerous checkpoint inhibitory molecules (e.g.,
CD73, PD-1) during aging and IL-2/anti-CD40 immunotherapy.
Further studies are required to examine the cross-talk between
macrophages, DCs and T cells in aging and cancer.
Cancer cachexia was evident in this study in all tumor-
bearing elderly mice. Cachexia is a comorbidity condition in
elderly cancer patients (Ali and Garcia, 2014) and can impair
the host’s ability to tolerate anti-cancer treatments (Ross et al.,
2004; Aapro et al., 2014; Kimura et al., 2015), as seen in
the present study by rapid weight loss with IL-2/anti-CD40
immunotherapy for the elderly mice. Interestingly, macrophage
depletion prevented treatment-induced weight loss in elderly
mice suggesting a role for macrophages in cachexia. Macrophages
can be a main source of pro-inflammatory mediators (Biswas
and Mantovani, 2010), including TNF-α and IL-6 (Thevaranjan
et al., 2017), which lead to skeletal muscle and adipose tissue
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catabolism, key factors in cachexia (Fearon et al., 2012; Laine
et al., 2013; Batista et al., 2016). Similarly, in a previous study
where IL-2/anti-CD40 was given systemically, macrophages from
elderly (16–22 months) female C57BL/6J but not young mice
increased production of TNF-α and IL-6 (Bouchlaka et al., 2013).
Macrophage production of these cytokines is reported to increase
with age in adipose tissue from elderly C57BL/6J mice (Lumeng
et al., 2011) suggesting an increased risk of muscle and adipose
tissue atrophy in the elderly. Therefore, in the presence of tumor-
derived inflammatory signals, macrophages may play a key role in
driving cancer cachexia in the elderly. Overall, our data suggests
that elderly mice may be more representative of the situation for
some human cancers and highly relevant to studies on the serious
problem of cancer cachexia.
During healthy aging in mice and humans there is a
progressive intrinsic loss of muscle mass and function termed
sarcopenia (Ali and Garcia, 2014). Sarcopenia is associated
with many factors including altered metabolism, denervation
(Barns et al., 2014) and inflammaging (Chhetri et al., 2018). In
male C57BL/6J mice sarcopenia is apparent from approximately
18 months and is pronounced by 24 months (Barns et al., 2014),
whilst in humans sarcopenia increases from about 50 years of
age (Sayer et al., 2013). This is taking into consideration that
aging in mice occurs for approximately 9 months compared with
>20 years in humans. The extent of sarcopenia varies between
muscles and is more pronounced in elderly male compared
with female C57BL/6J mice (White et al., 2016). Interestingly,
gender is also known to influence immune responses (Klein
et al., 2015); involving to some extent estrogen; (Laffont et al.,
2017), although few pre-clinical studies have examined the
influence of gender on anti-tumor immunity during aging.
Another contributing factor to consider is the impact of the
aging nervous system, since in healthy aging mice sarcopenia
is also associated with changes in peripheral nerves (Krishnan
et al., 2016). Pre-existing age-related neuronal changes might
exacerbate the reported neurotoxic effects that have been recently
reported for some immunotherapies (Stone and DeAngelis,
2016). It is not known to what extent this intrinsic propensity
for sarcopenia (and additional neuronal changes) with increasing
age may contribute to severity of cachexia in response to tumor
load in the elderly mice. Furthermore, the influence of gender also
needs to be considered in the context of age-related severity of
cachexia.
In summary, these new data highlight the role of macrophages
in tumor progression, particularly during aging where we
observed increased proportions and altered proliferation of
macrophages in the spleen and BM; two sites that can supply
macrophages to the tumor site. Macrophages from elderly
mice impaired anti-tumor T cell function and was associated
with poorer responses to IL-2/anti-CD40 immunotherapy.
Yet in young mice, macrophages were necessary for tumor
regression, suggesting macrophages become dysregulated
and more suppressive in elderly. Consequently, removal of
dysfunctional macrophages from elderly mice improved response
to treatment and prevented treatment-induced cachexia. These
studies highlight the potential for targeting macrophages to
improve response to anti-tumor immunotherapy in the elderly.
Further animal studies are required to determine the underlying
mechanisms behind macrophage dysfunction during aging, the
impact on cancer immunotherapy and interventions to help
reduce cancer cachexia in elderly humans.
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